GGrantIndex
← Leaderboards

Richard C. Reichman

University Of Rochester

Google Scholar ↗PubMed ↗ORCID ↗
$18,935,739
Attributed
$18,935,739
Total exposure
44
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.1M · FY2005–07
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07

Funding mix

By agency

NIH$18,935,739 · 44

By mechanism

U01$15,966,938 · 2
T32$1,966,965 · 1
M01$1,001,836 · 41

Top collaborators

No co-investigators on record.

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectAids TherapyHuman Therapy EvaluationHiv InfectionsAntiaids AgentDrug Screening /EvaluationCombination ChemotherapyPharmacokineticsProtease InhibitorDrug Adverse EffectLamivudineZidovudineAidsHuman Immunodeficiency Virus 1Clinical Trial Phase IPathologic ProcessAntiviral AgentsPatient Oriented ResearchLongitudinal Human StudyMycobacterium AviumIndinavirNucleoside AnalogOpportunistic Infections

Grant awards (82)

Units for HIV/AIDS Clinical Trials Networks$2,568,528
U01 · FY2007 · AI · contact PI
Training Program in Viral Diseases,Vaccines/ Biodefense$313,606
T32 · FY2007 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$1,660,691
U01 · FY2006 · AI · contact PI
Training Program in Viral Diseases,Vaccines/ Biodefense$381,587
T32 · FY2006 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$2,009,867
U01 · FY2005 · AI
Training Program in Viral Diseases,Vaccines/ Biodefense$425,905
T32 · FY2005 · AI
ACTG A5095: PHASE III, COMPARISON OF THREE PROTEASE INHIBITOR-SPARING REGIMENS$154,122
M01 · FY2005 · RR
ACTG A5001: LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL$94,727
M01 · FY2005 · RR
ACTG A5142: COMPARISON STUDY OF THREE ANTIRETROVIRAL TREATMENT REGIMENS IN HIV$87,961
M01 · FY2005 · RR
LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS &HIV-1 COINFECTED SUBJECTS$72,924
M01 · FY2005 · RR
TWICE &ONCE DAILY ANTIRETROVIRAL THERAPY, SELF ADMIN VS DIRECT OBSERVATION$43,604
M01 · FY2005 · RR
ACTG A5090: STUDY OF SELEGILINE TRANSDERMAL SYSTEM IN HIV COGNITIVE IMPAIRMENT$33,831
M01 · FY2005 · RR
ACTG A5068: INTERMITTENT WITHDRAWAL OF ART AS AN IMMUNIZATION STRATEGY$29,320
M01 · FY2005 · RR
ACTG A5030: TRIAL OF VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV VIREMIA$24,809
M01 · FY2005 · RR
A5186 TRIAL OF COMBINATION THERAPY ON TRIGLYCERIDE LEVELS IN SUBJECTS ON HAART T$24,058
M01 · FY2005 · RR
SAFETY AND EFFICACY OF SCH 417690 (AN ORALLY ADMINISTERED HIV-1 ENTRY INHIBITOR)$15,788
M01 · FY2005 · RR
A5163: PHASE II STUDY OF ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS$15,037
M01 · FY2005 · RR
ACTG 362: TRIAL TO DETERMINE TIME TO DEVELOPMENT OF AIDS COMPLICATIONS &INFECT$10,526
M01 · FY2005 · RR
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ OPPORTUNISITIC INFECTIONS$7,517
M01 · FY2005 · RR
ACTG 736: CEREBROSPINAL FLUID HIV-1 AND COGNITIVE FUNCTION IN INDIVIDUALS$6,766
M01 · FY2005 · RR
STUDY TO EVALUATE ANTIRETROVIRAL EFFECT OF MRK AD5 HIV VACCINE IN HIV-1 + INDIV$5,262
M01 · FY2005 · RR
A5170: PREDICTORS OF IMMUNOLOGIC &CLINICAL PROGRESSION IN SUBJECTS WHO STOP ART$4,511
M01 · FY2005 · RR
ACTG A5116: TWO POTENT SIMPLIFIED REGIMENS USING PI-SPARING REGIMEN$1,504
M01 · FY2005 · RR
ACTG A5077: VIROLOGIC STUDIES IN COMPARTMENTAL SAMPLES FROM HIV-INFECTED SUBJECT$751
M01 · FY2005 · RR
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$1,992,814
U01 · FY2004 · AI
Training Program in Viral Diseases,Vaccines/ Biodefense$426,260
T32 · FY2004 · AI
ACTG A5090: STUDY OF SELEGILINE TRANSDERMAL SYSTEM$32,173
M01 · FY2004 · RR
A5163: PHASE II STUDY OF ONCE-WEEKLY ALENDRONATE$22,189
M01 · FY2004 · RR
ACTG A5142: COMPARISON STUDY OF THREE ANTIRETROVIRAL TX$21,077
M01 · FY2004 · RR
ACTG 736: Cerebrospinal Fluid HIV-1 and Cognition$7,765
M01 · FY2004 · RR
ACTG A5117: DEVELOPMENT OF SYMMETRICAL POLYNEUROPATHY$7,765
M01 · FY2004 · RR
ACTG A5001: Longitudinal Linked Randomized Trial (ALLRT)$3,328
M01 · FY2004 · RR
ACTG A5093: PK INTERACTION B/W DEPO-PROVERA &PROTEASE$2,220
M01 · FY2004 · RR
ACTG A5116: Two Potent Simplified Regimens$1,108
M01 · FY2004 · RR
ACTG 362: Trial to Determine Time to development of AIDS Complications &infect$1,108
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$1,963,534
U01 · FY2003 · AI
Training Program in Viral Diseases,Vaccines/ Biodefense$419,607
T32 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$1,864,184
U01 · FY2002 · AI
ACTG 5051--INTERLEUKIN 2 COMBINATION W/ ANTIRETROVIRAL$0
M01 · FY2002 · RR
DONATION OF ONE UNIT OF BLOOD$0
M01 · FY2002 · RR
ACTG 368--A RANDOMIZED, DOUBLE BLIND, PHASE II STUDY OF INDINAVIR SULFATE$0
M01 · FY2002 · RR
ACTG 328-- STUDY OF RHIL2 BY IV OR SUBQ ADMIN IN SUBJECTS WITH HIV INFECTION$0
M01 · FY2002 · RR
ACTG 301--A RAND, DB, PC OF MEMANTINE FOR AIDS DEMENTIA COMPLEX$0
M01 · FY2002 · RR
ACTG 323/MSG40--USE OF FLUCONAZOLE AS CHRONIC SUPR THERAPY VS EPISODIC THERAPY$0
M01 · FY2002 · RR
ACTG 343--A PROSPECTIVE DB, TRIAL OF THREE THERAPYS OF ZDV, 3TC AND IDV$0
M01 · FY2002 · RR
ACTG 372:PH II PROLONGATION OF VIROLOGIC SUCC &FAIL PTS RECEIVE IND$0
M01 · FY2002 · RR
ACTG 362: TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN FOR MYCOBAC AVI$0
M01 · FY2002 · RR
ACTG 388: PHASE III TRIAL OF EFAVIRENZ OR NELFINAVIR IN COMBO W/ 3TC/$0
M01 · FY2002 · RR
ACTG 398: TRIAL OF AMPRENAVIR DUAL PROTEASE INHIBITOR REGIME IN COMBI$0
M01 · FY2002 · RR
ACTG A5025: S&E OF HYDROXYUREA IN SUBJECTS ON POTENT ANTIRETROVIRAL T$0
M01 · FY2002 · RR
ACTG 384--PROTEASE INHIBITOR/ REVERSE TRANSCRIPTASE INHI$0
M01 · FY2002 · RR
BOOSTER DOSE OF MEDI 501 IN VOLUNTEERS FROM MI-CP028$0
M01 · FY2002 · RR
ACTG 392--HIGH PROTEIN SUPPLEMENT IN HIV+ SUBJECTS$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$2,093,817
U01 · FY2001 · AI
ACTG 368--A RANDOMIZED, DOUBLE BLIND, PHASE II STUDY OF INDINAVIR SULFATE$19,613
M01 · FY2001 · RR
DONATION OF ONE UNIT OF BLOOD$19,613
M01 · FY2001 · RR
RDB, PHASE 3 INDINDAVIR SULFATE, ZDV, 3TC, SUBJECTS WITH HIV INFECTION$19,613
M01 · FY2001 · RR
INFLUENCE OF RISK STATUS FOR DISEASE PROGRESSION$19,613
M01 · FY2001 · RR
ACTG 328-- STUDY OF RHIL2 BY IV OR SUBQ ADMIN IN SUBJECTS WITH HIV INFECTION$19,613
M01 · FY2001 · RR
ATCG 290--RANDOMIZED STUDY OF THE VIROLOGIC AND IMMUNOLOGIC$19,613
M01 · FY2001 · RR
DONATION OF ONE UNIT OF BLOOD$19,613
M01 · FY2001 · RR
ACTG 343--A PROSPECTIVE DB, TRIAL OF THREE THERAPYS OF ZDV, 3TC AND IDV$19,613
M01 · FY2001 · RR
ACTG 323/MSG40--USE OF FLUCONAZOLE AS CHRONIC SUPR THERAPY VS EPISODIC THERAPY$19,613
M01 · FY2001 · RR
ACTG 301--A RAND, DB, PC OF MEMANTINE FOR AIDS DEMENTIA COMPLEX$19,613
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)$1,813,503
U01 · FY2000 · AI
DONATION OF ONE UNIT OF BLOOD$14,791
M01 · FY2000 · RR
OL, R, STUDY OF DELAVIRDINE MESYLATE W/ ZDV &INDINAVIR VS ZDV, 3TC &$14,791
M01 · FY2000 · RR
ACTG 323/MSG40--USE OF FLUCONAZOLE AS CHRONIC SUPR THERAPY VS EPISODIC THERAPY$14,791
M01 · FY2000 · RR
PH I STUDY OF S T &I OF MEDI 501, VIRUS LIKE PARTICLE (VLP) PAPPILOM$14,791
M01 · FY2000 · RR
ACTG 328-- STUDY OF RHIL2 BY IV OR SUBQ ADMIN IN SUBJECTS WITH HIV INFECTION$14,791
M01 · FY2000 · RR
ACTG 368--A RANDOMIZED, DOUBLE BLIND, PHASE II STUDY OF INDINAVIR SULFATE$0
M01 · FY2000 · RR
ACTG 392--HIGH PROTEIN SUPPLEMENT IN HIV+ SUBJECTS$0
M01 · FY2000 · RR
BOOSTER DOSE OF MEDI 501 IN VOLUNTEERS FROM MI-CP028$0
M01 · FY2000 · RR
ACTG 5051--INTERLEUKIN 2 COMBINATION W/ ANTIRETROVIRAL$0
M01 · FY2000 · RR
ACTG 384--PROTEASE INHIBITOR/ REVERSE TRANSCRIPTASE INHI$0
M01 · FY2000 · RR
ACTG A5025: S&E OF HYDROXYUREA IN SUBJECTS ON POTENT ANTIRETROVIRAL T$0
M01 · FY2000 · RR
ACTG 398: TRIAL OF AMPRENAVIR DUAL PROTEASE INHIBITOR REGIME IN COMBI$0
M01 · FY2000 · RR
ACTG 388: PHASE III TRIAL OF EFAVIRENZ OR NELFINAVIR IN COMBO W/ 3TC/$0
M01 · FY2000 · RR
ACTG 362: TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN FOR MYCOBAC AVI$0
M01 · FY2000 · RR
ACTG 372:PH II PROLONGATION OF VIROLOGIC SUCC &FAIL PTS RECEIVE IND$0
M01 · FY2000 · RR
ACTG 343--A PROSPECTIVE DB, TRIAL OF THREE THERAPYS OF ZDV, 3TC AND IDV$0
M01 · FY2000 · RR
ACTG 301--A RAND, DB, PC OF MEMANTINE FOR AIDS DEMENTIA COMPLEX$0
M01 · FY2000 · RR